The effect of 17-alpha hydroxyprogesterone caproate on the risk of gestational diabetes in singleton or twin pregnancies.
OBJECTIVE
To compare the rates of gestational diabetes among women who received serial doses of 17-alpha hydroxyprogesterone caproate vs placebo.


METHODS
Secondary analysis of 2 double-blind randomized placebo-controlled trials of 17-alpha hydroxyprogesterone caproate given to women at risk for preterm delivery. The incidence of gestational diabetes was compared between women who received 17-alpha hydroxyprogesterone caproate or placebo.


RESULTS
We included 1094 women; 441 had singleton and 653 had twin gestations. Combining the 2 studies, 616 received 17-alpha hydroxyprogesterone caproate and 478 received placebo. Among singleton and twin pregnancies, rates of gestational diabetes were similar in women receiving 17-alpha hydroxyprogesterone caproate vs placebo (5.8% vs 4.7%; P = .64 and 7.4% vs 7.6%; P = .94, respectively). In the multivariable model, progesterone was not associated with gestational diabetes (adjusted odds ratio, 1.04; 95% confidence interval, 0.62-1.73).


CONCLUSIONS
Weekly administration of 17-alpha hydroxyprogesterone caproate is not associated with higher rates of gestational diabetes in either singleton or twin pregnancies.
Gyamfi
Cynthia
C
Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, USA.
Horton
Amanda L
AL
Momirova
Valerija
V
Rouse
Dwight J
DJ
Caritis
Steve N
SN
Peaceman
Alan M
AM
Sciscione
Anthony
A
Meis
Paul J
PJ
Spong
Catherine Y
CY
Dombrowski
Mitchell
M
Sibai
Baha
B
Varner
Michael W
MW
Iams
Jay D
JD
Mercer
Brian M
BM
Carpenter
Marshall W
MW
Lo
Julie
J
Ramin
Susan M
SM
O'Sullivan
Mary Jo
MJ
Miodovnik
Menachem
M
Conway
Deborah
D
D000077713:17 alpha-Hydroxyprogesterone Caproate; D016640:Diabetes, Gestational / Q000453:epidemiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D015999:Multivariate Analysis; D011247:Pregnancy; D011272:Pregnancy, Multiple; D011372:Progestins / Q000627:therapeutic use*; D012307:Risk Factors
D006908:Hydroxyprogesterones; D011372:Progestins; D000077713:17 alpha-Hydroxyprogesterone Caproate